Inhibition of Radiation and Temozolomide-Induced Glioblastoma Invadopodia Activity Using Ion Channel Drugs

Marija Dinevska 1, Natalia Gazibegovic 2, Andrew P. Morokoff 1,3, Andrew H. Kaye 1,4, Katharine J. Drummond 1,3, Theo Mantamadiotis 1,5 and Stanley S. Stylli 1,3,*

1 Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville 3050, Victoria, Australia; mdinevska@student.unimelb.edu.au (M.D.); morokoff@unimelb.edu.au (A.P.M.); a.kaye@unimelb.edu.au (A.H.K.); kjd@unimelb.edu.au (K.J.D.); theo.mantamadiotis@unimelb.edu.au (T.M.)

2 Victoria University, St. Albans 3021, Victoria, Australia; natalia.gazibegovic@outlook.com

3 Department of Neurosurgery, The Royal Melbourne Hospital, Parkville 3050, Victoria, Australia

4 Hadassah University Medical Centre, Jerusalem 91120, Israel

5 Department of Microbiology & Immunology, School of Biomedical Sciences, The University of Melbourne, Parkville 3010, Victoria, Australia

* Correspondence: stanley.stylli@mh.org.au or sstylli@unimelb.edu.au

Received: 8 September 2020; Accepted: 30 September 2020; Published: 8 October 2020

Simple Summary: Glioblastoma accounts for approximately 40–50% of all primary brain cancers and is a highly aggressive cancer that rapidly disseminates within the surrounding normal brain. Dynamic actin-rich protrusions known as invadopodia facilitate this invasive process. Ion channels have also been linked to a pro-invasive phenotype and may contribute to facilitating invadopodia activity in cancer cells. The aim of our study was to screen ion channel-targeting drugs for their cytotoxic efficacy and potential anti-invadopodia properties in glioblastoma cells. We demonstrated that the targeting of ion channels in glioblastoma cells can lead to a reduction in invadopodia activity and protease secretion. Importantly, the candidate drugs exhibited a significant reduction in radiation and temozolomide-induced glioblastoma cell invadopodia activity. These findings support the proposed pro-invasive role of ion channels via invadopodia in glioblastoma, which may be ideal therapeutic targets for the treatment of glioblastoma patients.

Abstract: Glioblastoma (GBM) is the most prevalent and malignant type of primary brain cancer. The rapid invasion and dissemination of tumor cells into the surrounding normal brain is a major driver of tumor recurrence, and long-term survival of GBM patients is extremely rare. Actin-rich cell membrane protrusions known as invadopodia can facilitate the highly invasive properties of GBM cells. Ion channels have been proposed to contribute to a pro-invasive phenotype in cancer cells and may also be involved in the invadopodia activity of GBM cells. GBM cell cytotoxicity screening of several ion channel drugs identified three drugs with potent cell killing efficacy: flunarizine dihydrochloride, econazole nitrate, and quinine hydrochloride dihydrate. These drugs demonstrated a reduction in GBM cell invadopodia activity and matrix metalloproteinase-2 (MMP-2) secretion. Importantly, the treatment of GBM cells with these drugs led to a significant reduction in radiation/temozolomide-induced invadopodia activity. The dual cytotoxic and anti-invasive efficacy of these agents merits further research into targeting ion channels to reduce GBM malignancy, with a potential for future clinical translation in combination with the standard therapy.

Keywords: glioma; glioblastoma; invasion; invadopodia; ion channels; drug repurposing
1. Introduction

Malignant brain tumors are among the most aggressive cancers, resulting in impaired health-related quality of life and survival measured in months or a few years [1]. As classified by the World Health Organization (WHO), glioblastoma (GBM) is a highly malignant grade IV astrocytoma accounting for approximately 50% of all gliomas [2–4]. Although GBM has an incidence of less than 10 per 100,000, it is incurable; thus, the burden of disease on patients and carers remains significant, resulting in an average loss of 12 years of life [5].

The current therapeutic regime for GBM patients follows the “Stupp Protocol”, which involves maximal safe surgical resection of the tumor followed by radiotherapy (RT) and concomitant chemotherapy with temozolomide (TMZ), an oral DNA alkylating agent and subsequent adjuvant TMZ for 6–12 months [6]. Despite a modest increase in survival since the introduction of TMZ (14.6 month median survival), 50% of GBM patients do not respond to TMZ, developing resistance to both RT and TMZ [7]. In addition, GBM widely infiltrates the surrounding brain parenchyma [8]. This invasive capacity hinders surgical resection, making gross tumor debulking impossible with inevitable tumor recurrence within 1–2 cm of the resection cavity [8,9].

Cancer cell invasion is a multi-step process orchestrated by tumor cell interactions with the tumor microenvironment [10]. This process is initiated by cell polarization and adhesion to the extracellular matrix (ECM), which is followed by acquired cancer cell mobility and ECM degradation [8]. More specifically, research has indicated that dynamic actin-rich subcellular protrusions known as invadopodia are integral in facilitating cancer cell invasion [11]. These structures serve to proteolytically degrade the ECM through the complex interactions within a network of signaling molecules and proteins [12,13]. Invadopodia can extend up to 8 µm into the surrounding environment and have a diameter ranging from 0.1 to 0.8 µm [12]. The physical force generated by actin polymerization and the action of transmembrane and secreted matrix metalloproteinases (MMP-2 and -9) in ECM degradation are integral to the invadopodia-mediated invasion of malignant cells [14]. Numerous proteins, including Tks5 (Tyrosine Kinase substrate with 5 SH3 domains) and cortactin, are involved in the processes required for the biogenesis of invadopodia, which include cell signaling, adhesion, and actin remodeling [15]. Our laboratory has previously demonstrated that expression levels of the invadopodia regulator Tks5 in human glioma biopsies are related to prognosis [16]. Importantly, the amplification of the cortactin gene (CTTN) is evident in a number of cancers, correlating with enhanced tumor invasiveness and poor prognosis [17,18].

Ion channels regulate several cancer promoting processes, including tumor cell invasion [19,20]. Under physiological conditions, potassium, sodium, and calcium channels are responsible for maintaining intracellular ionic balance, cell shape, and cell volume [21]. However, during tumorigenesis, the altered expression of ion channel genes can lead to the dysregulation of normal cellular functions, including proliferation, migration, and apoptosis [22]. For example, potassium channels, such as calcium-activated potassium channels (that is, KCa3.1), have been linked to enhanced invasion via the regulation of cellular ionic balance [19,23–25]. The gene encoding KCa3.1, KCNN4, is overexpressed in 32% of gliomas and correlates with shorter survival [26]. Additionally, potassium channels have been described to contribute to cancer cell invasion via their interaction with molecules associated with invadopodia formation, such as focal adhesion kinase (FAK), integrins, and cortactin [25]. Likewise, voltage-gated calcium channels (VGCCs) and non-voltage activated calcium permeable channels are associated with malignant transformations in a number of cancers, including glioma [27]. A study by Zhang et al. [28] demonstrated a decrease in cell migration in human GBM cell lines following the inhibition of T-type Ca$^{2+}$ channels (low-voltage activated channels). Under resting membrane conditions, these ion channels play an integral role in the maintenance of intracellular Ca$^{2+}$ and have been linked to tumor cell migration and invasion in GBM cells [29]. In the context of tumor cell invasion, the role of ion channels is only beginning to be understood [19]. The proposed influence of ion channels on actin cytoskeletal rearrangement and various proteins including cortactin and integrins may contribute to mechanisms mediating invadopodia formation and activity in cancer
cells [30,31]. This highlights the potential for ion channel blockers to target invadopodia and inhibit GBM cell invasion.

Over the past decade, the standard of care for GBM has remained unchanged, emphasizing the urgent need for drug discovery and development. This process requires high-throughput screening of candidate compounds, followed by extensive pre-clinical and clinical studies [32]. However, major limitations with this approach include both the time from the initial studies to clinical implementation (ranging from 11.4 to 13.5 years) and the associated costs ($161 million to $1.8 billion) [32]. For this reason, drug repurposing has become an increasingly attractive option. This is advantageous as it offers a reduction in the time required for pre-clinical and clinical studies and the associated costs, as drug toxicity, pharmacokinetics, dosage, and safety are already understood [33].

In this study, we investigated the cytotoxicity and anti-invasion activity of a panel of ion channel-binding drugs on GBM cells. The aim of this work was to screen a panel of 20 ion channel-targeting drugs for their ability to inhibit GBM cell viability and invadopodia activity.

2. Results

2.1. GBM Tissue Exhibits Increased Invadopodia Regulator and Ion Channel Gene Expression

To investigate the clinical relevance of invadopodia regulator (Table 1) and ion channel (Table 2) genes in glioma, we used the online database, Oncomine\textsuperscript{TM}. The expression levels of the pro-invadopodia regulators cortactin, MMP-2, Src, NWASP (Neural Wiskott-Aldrich syndrome protein), Tks4 (Tyrosine Kinase substrate with 4 SH3 domains), Tks5, and Nck (non-catalytic region of tyrosine kinase adaptor protein), and ion channel (calcium, sodium, and potassium) genes in GBM and non-tumor brain tissue were examined. MMP-2 and Nck1 (non-catalytic region of tyrosine kinase adaptor protein 1) were the most frequently overexpressed invadopodia regulators in GBM compared to non-tumor brain tissue (Table 1).

The data presented in Table 2 demonstrate that the potassium and calcium ion channels, KCNH2 and CACNA1C, were most frequently overexpressed in GBM tissue compared to normal tissue. Subsequently, the SurvExpress online database for cancer gene expression data was used to examine the clinical relevance of invadopodia regulators and ion channel gene expression in GBM.

Figure 1 demonstrates poorer survival outcomes for high gene expression of the pro-invadopodia regulator, CTTN, or ion channel, CACNA1F. The co-expression of CTTN and CACNA1F reveals a further impact on survival, and additional combinations are listed in Table 3. Together, these data suggests a role for ion channels in the process of glioma cell invasion mediated by invadopodia.

![Figure 1](image)

**Figure 1.** Co-expression of invadopodia regulator and ion channel genes correlates with poor GBM patient survival. (A) High invadopodia regulator (cortactin gene, CTTN), (B) ion channel (CACNA1S), and (C) combined gene expression indicates significantly poorer survival outcomes in GBM patients from the Nutt Louis dataset (deposited within the SurvExpress database). The Kaplan–Meier plots show the two risk groups, the log-rank test of differences between risk groups, the hazard ratio estimate, and the concordance indices.
Table 1. Invadopodia regulator genes are overexpressed in glioblastoma (GBM) tissue compared to normal brain tissue.

| Invadopodia Marker | Number of GBM Tissue Samples | Number of Normal Tissue Samples | Total Measured Genes | Mean Fold Change (Log2) | p Value | Sample Type | Platform | Study |
|--------------------|------------------------------|--------------------------------|----------------------|------------------------|---------|-------------|----------|-------|
| CTTN               | 542                          | 10                             | 12,624               | 1.353                  | $3 \times 10^{-3}$ | mRNA       | Human Genome U2A | TCGA  |
| MMP2               | 27                           | 4                              | 14,836               | 6.426                  | $5.0 \times 10^{-4}$ | mRNA       | ND          | Bredel Brain 2 [34] |
| MMP2               | 30                           | 3                              | 9957                 | 4.537                  | $3.0 \times 10^{-3}$ | mRNA       | ND          | Liang [35]       |
| MMP2               | 80                           | 4                              | 19,574               | 2.92                   | $2.98 \times 10^{-4}$ | mRNA       | Human Genome U2A | Murat [36] |
| MMP2               | 81                           | 23                             | 19,574               | 3.548                  | $7.99 \times 10^{-16}$ | mRNA       | Human Genome U2A | Sun [37] |
| MMP2               | 542                          | 10                             | 12,624               | 4.818                  | $4.06 \times 10^{-10}$ | mRNA       | Human Genome U2A | TCGA  |
| Nck1               | 27                           | 4                              | 14,836               | 1.717                  | $1.0 \times 10^{-2}$ | mRNA       | ND          | Bredel Brain 2 [34] |
| Nck1               | 30                           | 3                              | 9957                 | 1.626                  | $1.9 \times 10^{-2}$ | mRNA       | ND          | Liang [35]       |
| Nck1               | 80                           | 4                              | 19,574               | 1.885                  | $5.0 \times 10^{-3}$ | mRNA       | Human Genome U2A | Murat [36] |
| Nck1               | 81                           | 23                             | 19,574               | 1.305                  | $5.41 \times 10^{-7}$ | mRNA       | Human Genome U2A | Sun [37] |
| Nck2               | 542                          | 10                             | 12,624               | 2.056                  | $4.06 \times 10^{-9}$ | mRNA       | Human Genome U2A | TCGA  |
| Nck2               | 80                           | 4                              | 19,574               | 1.135                  | $2.0 \times 10^{-3}$ | mRNA       | Human Genome U2A | Murat [36] |
| NWASP              | 81                           | 23                             | 19,574               | 1.338                  | $1.10 \times 10^{-2}$ | mRNA       | Human Genome U2A | Sun [37] |
| Src                | 80                           | 4                              | 19,574               | 1.035                  | $4.50 \times 10^{-2}$ | mRNA       | Human Genome U2A | Murat [36] |
| Src                | 81                           | 23                             | 19,574               | 1.601                  | $2.0 \times 10^{-3}$ | mRNA       | Human Genome U2A | Sun [37] |
| Tks4               | 27                           | 4                              | 14,836               | 3.237                  | $1.12 \times 10^{-4}$ | mRNA       | ND          | Bredel Brain 2 [34] |
| Tks4               | 30                           | 3                              | 9957                 | 1.492                  | $1.40 \times 10^{-2}$ | mRNA       | ND          | Liang [35]       |
| Tks4               | 80                           | 4                              | 19,574               | 2.241                  | $1.32 \times 10^{-6}$ | mRNA       | Human Genome U2A | Murat [36] |
| Tks4               | 81                           | 23                             | 19,574               | 2.194                  | $2.50 \times 10^{-4}$ | mRNA       | Human Genome U2A | Sun [37] |
| Tks5               | 27                           | 4                              | 14,836               | 1.399                  | $4.80 \times 10^{-2}$ | mRNA       | ND          | Bredel Brain 2 [34] |
| Tks5               | 22                           | 7                              | 7689                 | 1.263                  | $5.00 \times 10^{-3}$ | mRNA       | ND          | Yamanaka [38]    |

mRNA expression levels of invadopodia regulators in GBM and normal brain tissue were retrieved from the Oncomine database (mean fold change versus normal brain and overall p value in that dataset are displayed). The Student t-test is used to generate the p value. Gene expression data have been log transformed and normalized. Not defined (ND); Human Genome U2A—Human Genome U133 Plus 2.0 Array; TCGA—The Cancer Genome Atlas; MMP2—matrix metalloproteinase-2; NWASP—Neural Wiskott–Aldrich syndrome protein; Tks4—tyrosine kinase substrate with 4 SH3 domains; Tks5—tyrosine kinase substrate with 5 SH3 domains; Nck—non-catalytic region of tyrosine kinase adaptot protein; mRNA—messenger RNA; RNA—ribonucleic acid.
Table 2. Ion channel genes are overexpressed in GBM tissue compared to normal brain tissue.

| Ion Channel Gene | Number of GBM Tissue Samples | Number of Normal Tissue Samples | Total Measured Genes | Mean Fold Change (Log2) | p Value | Sample Type | Platform | Study       |
|------------------|------------------------------|---------------------------------|----------------------|------------------------|---------|-------------|----------|-------------|
| KCNH2            | 106                          | 32                              | 18,823               | 1.175                  | 3.49 × 10^{-13} | DNA       | RefSeq Genes | Beroukhim Brain [39] |
| KCNA5            | 107                          | 32                              | 18,823               | 1.054                  | 2.15 × 10^{-4}  | DNA       | RefSeq Genes | Beroukhim Brain [39] |
| KCNJ10           | 107                          | 33                              | 18,823               | 1.041                  | 2.00 × 10^{-3}  | DNA       | RefSeq Genes | Beroukhim Brain [39] |
| KCNB1            | 107                          | 33                              | 18,823               | 1.064                  | 2.00 × 10^{-3}  | DNA       | RefSeq Genes | Beroukhim Brain [39] |
| CACNA1S          | 107                          | 33                              | 18,823               | 1.041                  | 3.20 × 10^{-2}  | DNA       | RefSeq Genes | Beroukhim Brain [39] |
| CACNA1C          | 107                          | 33                              | 18,823               | 1.041                  | 1.20 × 10^{-2}  | DNA       | RefSeq Genes | Beroukhim Brain [39] |
| KCNN4            | 21                           | 3                               | 14,836               | 2.219                  | 1.40 × 10^{-2}  | mRNA      | ND         | Bredel Brain 2 [34] |
| CACNA1D          | 27                           | 4                               | 14,836               | 1.377                  | 6.00 × 10^{-3}  | mRNA      | ND         | Bredel Brain 2 [34] |
| CACNA1C          | 22                           | 3                               | 19,574               | 8.62                   | 6.00 × 10^{-3}  | mRNA      | Human Genome U2A Lee Brain [40] |
| KCNH2            | 22                           | 3                               | 19,574               | 1.869                  | 1.00 × 10^{-3}  | mRNA      | Human Genome U2A Lee Brain [40] |
| KCNB1            | 22                           | 3                               | 19,574               | 2.325                  | 2.10 × 10^{-2}  | mRNA      | Human Genome U2A Lee Brain [40] |
| CACNA1D          | 22                           | 3                               | 19,574               | 3.293                  | 3.85 × 10^{-4}  | mRNA      | Human Genome U2A Lee Brain [40] |
| KCNH2            | 80                           | 4                               | 19,574               | 1.252                  | 5.00 × 10^{-3}  | mRNA      | Human Genome U2A Murat Brain [36] |
| KCNH2            | 27                           | 7                               | 8603                 | 1.101                  | 1.20 × 10^{-2}  | mRNA      | Human Genome U95A Shai Brain [41] |
| KCNH2            | 81                           | 23                              | 19,574               | 2.142                  | 1.70 × 10^{-2}  | mRNA      | Human Genome U2A Sun Brain [37] |
| KCNH2            | 542                          | 10                              | 12,624               | 1.094                  | 1.20 × 10^{-2}  | mRNA      | Human Genome U2A TCGA 2 |
| KCNH2            | 582                          | 37                              | 18,823               | 1.320                  | 4.80 × 10^{-169} | DNA       | RefSeq Genes | TCGA 2 |
| KCNA5            | 582                          | 37                              | 18,823               | 1.034                  | 5.75 × 10^{-8}  | DNA       | RefSeq Genes | TCGA 2 |
| KCNJ10           | 582                          | 37                              | 18,823               | 1.061                  | 1.65 × 10^{-46} | DNA       | RefSeq Genes | TCGA 2 |
| KCNB1            | 582                          | 37                              | 18,823               | 1.126                  | 3.54 × 10^{-68} | DNA       | RefSeq Genes | TCGA 2 |
| KCNN4            | 582                          | 37                              | 18,823               | 1.046                  | 6.02 × 10^{-10} | DNA       | RefSeq Genes | TCGA 2 |
| SCN5A            | 582                          | 37                              | 18,823               | 1.019                  | 6.64 × 10^{-5}  | DNA       | RefSeq Genes | TCGA 2 |
| SCN8A            | 582                          | 37                              | 18,823               | 1.012                  | 1.60 × 10^{-2}  | DNA       | RefSeq Genes | TCGA 2 |
Table 2. Cont.

| Ion Channel Gene | Number of GBM Tissue Samples | Number of Normal Tissue Samples | Total Measured Genes | Mean Fold Change (Log2) | p Value | Sample Type | Platform | Study |
|------------------|-----------------------------|--------------------------------|----------------------|------------------------|---------|-------------|----------|-------|
| CACNA1S          | 582                         | 37                             | 18,823               | 1.055                  | 2.28 × 10⁻³⁰ | DNA        | RefSeq Genes | TCGA 2 |
| CACNA1C          | 582                         | 37                             | 18,823               | 1.032                  | 1.11 × 10⁻⁷  | DNA        | RefSeq Genes | TCGA 2 |
| CACNA1D          | 582                         | 37                             | 18,823               | 1.013                  | 7.00 × 10⁻³  | DNA        | RefSeq Genes | TCGA 2 |
| CACNA1B          | 582                         | 37                             | 18,823               | 1.019                  | 1.00 × 10⁻³  | DNA        | RefSeq Genes | TCGA 2 |
| CACNA1G          | 582                         | 37                             | 18,823               | 1.027                  | 4.56 × 10⁻¹⁶ | DNA        | RefSeq Genes | TCGA 2 |

mRNA and DNA expression levels of ion channels in GBM and normal brain tissue were retrieved from the Oncomine database (mean fold change versus normal brain and overall p value in that dataset are displayed. The Student t-test is used to generate the p value.). Gene expression data have been log transformed and normalized. Not defined (ND); Human Genome U2A—Human Genome U133 Plus 2.0 Array; Human Genome U95A—Human Genome U95A-Av2 Array; DNA—deoxyribonucleic acid; mRNA—messenger RNA; RNA—ribonucleic acid; TCGA—The Cancer Genome Atlas; KCNH2—hERG (the human Ether-à-go-go-Related Gene); KCNA5—Potassium voltage-gated channel, shaker-related subfamily, member 5; KCNJ10—Potassium Inwardly Rectifying Channel Subfamily J Member 10; KCNB1—Potassium Voltage-Gated Channel Subfamily B Member 1; CACNA1S—Calcium Voltage-Gated Channel Subunit Alpha1 S; CACNA1C—Calcium Voltage-Gated Channel Subunit Alpha1 C; KCNN4—Potassium Calcium-Activated Channel Subfamily N Member 4; CACNA1D—Calcium Voltage-Gated Channel Subunit Alpha1 D; CACNA1G—Calcium Voltage-Gated Channel Subunit Alpha1 G; SCN5A—Sodium Voltage-Gated Channel Alpha Subunit 5; SCN8A—Sodium Voltage-Gated Channel Alpha Subunit 8; RefSeq—Reference Sequence.
Table 3. Pro-invadopodia regulator and ion channel gene co-expression correlates with shorter survival in GBM patients.

| Gene      | Study Dataset                  | Number of Patients | p-Value       | Concordance Index |
|-----------|--------------------------------|--------------------|---------------|------------------|
| CTTN      | Nutt Louis [42]                | 50                 | 2.12 × 10⁻⁵   | 65.39            |
| CTTN+CACNA1F | Nutt Louis [42]               | 50                 | 4.49 × 10⁻⁶   | 67.25            |
| MMP2      | Freije Nelson GPL96 [43]       | 85                 | 5.95 × 10⁻³   | 59.74            |
| MMP9      | Freije Nelson GPL96 [43]       | 85                 | 2.18 × 10⁻³   | 59.84            |
| Nck       | Freije Nelson GPL96 [43]       | 85                 | 1.05 × 10⁻³   | 62.01            |
| SH3PXD2A  | Yamanaka Nishio [38]          | 29                 | 3.80 × 10⁻²   | 77.89            |
| Src       | Lee Nelson GPL570 [40]        | 27                 | 3.80 × 10⁻²   | 62.36            |
| Src+CACNA1D | Lee Nelson GPL570 [40]       | 27                 | 2.10 × 10⁻²   | 64.94            |
| Src+CACNA1G | Lee Nelson GPL570 [40]       | 27                 | 3.04 × 10⁻²   | 58.91            |
| Src+CACNA1S | Lee Nelson GPL570 [40]       | 27                 | 3.39 × 10⁻²   | 61.21            |
| Src+KCNB1  | Lee Nelson GPL570 [40]        | 27                 | 3.39 × 10⁻²   | 61.78            |
| Src+SCN8A  | Lee Nelson GPL570 [40]        | 27                 | 2.10 × 10⁻²   | 60.92            |
| Src       | Nutt Louis [42]               | 50                 | 1.10 × 10⁻²   | 56.48            |
| Src+CACNA1F | Nutt Louis [42]               | 50                 | 4.10 × 10⁻³   | 62.49            |
| Src+CACNA1H | Nutt Louis [42]               | 50                 | 6.58 × 10⁻³   | 65.8             |
| Src       | GBM TCGA                      | 538                | 5.76 × 10⁻³   | 54.65            |
| Src+CACNA1C | GBM TCGA                    | 538                | 6.60 × 10⁻³   | 54.68            |
| Src+CACNA1G | GBM TCGA                    | 538                | 7.24 × 10⁻³   | 54.67            |
| Src+CACNA1H | GBM TCGA                    | 538                | 7.75 × 10⁻³   | 54.59            |
| Src+KCN5A  | GBM TCGA                      | 538                | 7.48 × 10⁻³   | 54.59            |
| Src+KCNN4  | GBM TCGA                      | 538                | 7.03 × 10⁻³   | 54.82            |

Co-expression of pro-invadopodia regulator and ion channel genes correlates with poorer GBM patient outcome as determined by analysis of GBM-derived datasets in the SurvExpress online database for cancer gene expression (the log-rank test was used to generate the p value).

2.2. GBM Cells Form Functional Invadopodia and Express Invadopodia Regulator Proteins

Invadopodia are actin-rich protrusions that facilitate the invasion of tumor cells from the tumor bulk into the surrounding healthy parenchyma [12,13]. MMPs (specifically MMP-2 and MMP-9) are enriched and secreted at the tips of invadopodia, thus mediating the proteolytic degradation of the ECM [11]. We utilized gelatin-based zymography to examine the conditioned medium isolated from
three GBM cell lines and determine the extracellular secreted levels of MMP-2 and MMP-9. Analysis of the conditioned media of the LN229, U87MG, and MU41 GBM cell lines revealed the presence of pro-MMP-2 (72 kDa) and active-MMP-2 (65 kDa). The LN229 cell line displayed the highest level of MMP-2 secretion, while the U87MG cell line showed the least (Figure 2A).

Several invadopodia regulator proteins, including Tks5, Src, and cortactin, participate in the formation and matrix-degrading activity of invadopodia. Therefore, we next examined the expression of these proteins in the LN229, U87MG, and MU41 cell lines (Figure 2B). The protein expression profile

![Figure 2](Image)

**Figure 2.** GBM cell lines secrete MMP-2 and form functional fluorescein isothiocyanate (FITC)–gelatin degrading invadopodia. (A) Gelatin-based zymogram analysis of LN229, U87MG, and MU41 cells cultured in serum-free conditioned media for 24 h showing MMP-2 activity. (B) Western blot analysis of GBM cell lines for a range of pro-invadopodia regulator proteins (Src, NWASP, MMP-2, Nck, phospho-cortactin, cortactin, and TKS5), the uncropped Western Blot figure is in Figure S2 (C) LN229, U87MG, and MU41 cells were plated on a thin film of cross-linked FITC-labeled gelatin for 24 h. Cells were stained with rhodamine phalloidin (red) to visualize actin filaments and DAPI (4′,6-diamidino-2-phenylindole) (blue) for cell nuclei. FITC–gelatin degradation is evident as black areas devoid of FITC-labeled gelatin. Images were acquired with a 60× oil immersion lens using a Nikon A1 confocal system. (D) Quantification of the basal invadopodia-mediated FITC–gelatin degradation. Representative of n = 3 independent experiments, error bars represent SEM. Scale bar = 20 µm.
of these regulators varied across cell lines, with Tks5 highly expressed in LN229 cells. Cortactin was highly expressed in the MU41 and LN229 cell lines. Notably, Src, MMP-2, and NWASP were detected at higher levels in the MU41 cell line.

As the GBM cells secreted MMP-2 and expressed a range of invadopodia regulator proteins, we next used a fluorescent gelatin matrix degradation assay to determine whether the GBM cell lines could form functional invadopodia. This assay, which measures MMP-2-mediated invasion by determining the clearance of fluorescein isothiocyanate (FITC)-labeled gelatin (absence of green) colocalized with rhodamine phalloidin actin-stained puncta, showed activity in the three GBM cell lines (Figure 2C). LN229 cells exhibited the highest FITC–gelatin degrading activity, followed by MU41 and U87MG cells (Figure 2D). This observation was consistent with the levels of MMP-2 secreted by each cell line (Figure 2A).

To further verify the presence of invadopodia, we co-stained GBM cells for Tks5 and cortactin as they colocalize with invadopodia and are integral for invadopodia formation and activity. As demonstrated in Figure 3, the co-localization of Tks5/cortactin with actin puncta validated the presence of invadopodia in the LN229, U87MG, and MU41 GBM cell lines.

**Figure 3.** Cortactin and Tks5 co-localize with actin in GBM cell invadopodia. LN229 and MU41 cells were seeded on FITC-labeled gelatin coverslips for 24 h prior to fixing and staining for rhodamine phalloidin to probe for F-actin filaments, cortactin, and Tks5 primary antibodies and an Alexa 405 secondary antibody (blue). Images were acquired with a 60× oil immersion lens using a Nikon A1 confocal system. Images displayed co-localization with actin puncta as follows: LN229 ((A)-cortactin), MU41 ((B)-cortactin), LN229 ((C)-Tks5), and MU41 ((D)-Tks5). White arrows denote co-localization with cortactin or Tks5 and actin puncta. Figure is representative of n = 3 experiments. Scale bar = 20 µm.
2.3. Ion Channel-Targeting Drugs Reduce GBM Cell Viability

The current standard of care for GBM patients is inadequate, and there is an urgent need to develop additional treatment options to target tumor cells that survive radiotherapy and chemotherapy. To identify ion channel-binding drugs that can kill GBM cells, we screened 20 drugs (Table 4) that inhibit ion channels (It must be noted that flunarizine dihydrochloride is the only ion channel drug in the list that is not currently FDA (Food and Drug Administration)-approved for clinical use in the USA). The drugs were first screened for their ability to reduce GBM cell viability using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell proliferation assay and then screened for their anti-invasive properties and regulation of invadopodia activity. The cytotoxicity of the 20 ion channel drugs was assessed across a range of concentrations (0.01, 0.1, 1, and 10 µM) in the three GBM cell lines (Figure S1).

Table 4. Ion channel drugs used in this study.

| Drug                        | Indication                  | Ion Channel |
|-----------------------------|-----------------------------|-------------|
| Amiloride hydrochloride dihydrate | Cardiovascular disease | Sodium      |
| Ouabain                     | Neurological disease        | Sodium      |
| Oxcarbazepine               | Neurological disease        | Sodium      |
| Primidone                   | Neurological disease        | Sodium      |
| Procaine hydrochloride      | Neurological disease        | Sodium      |
| Zonisamide                  | Neurological disease        | Sodium      |
| Azelnidipine                | Neurological disease        | Calcium     |
| Cinepazide maleate          | Inflammation                | Calcium     |
| Diltiazem hydrochloride     | Cardiovascular disease      | Calcium     |
| Econazole nitrate           | Neurological disease        | Calcium     |
| Flunarizine dihydrochloride | Neurological disease        | Calcium     |
| Nicardipine hydrochloride   | Neurological disease        | Calcium     |
| Nilvadipine                 | Cardiovascular disease      | Calcium     |
| Glimiperide                 | Type 2 diabetes mellitus    | Potassium   |
| Glyburide                   | Endocrinology               | Potassium   |
| Nateglinide                 | Immunology                  | Potassium   |
| Quinine hydrochloride dihydrate | Cardiovascular disease   | Potassium   |
| Repaglinide                 | Endocrinology               | Potassium   |
| Tolbutamide                 | Type 2 diabetes mellitus    | Potassium   |

The degree of cytotoxicity varied amongst the cell lines and drugs. To rank the drugs based on cytotoxic efficacy, a 20–30% threshold reduction in cell viability across the concentrations was applied. This identified the three most potent drugs: flunarizine dihydrochloride, econazole nitrate, and quinine hydrochloride dihydrate, which we further investigated.

2.4. Ion Channel Drugs Reduce MMP-2 Secretion and Invasion

Following the shortlisting of ion channel drugs based on their cytotoxicity profiles, we examined the impact of the drugs on MMP-2 secretion. LN229 and MU41 cells were investigated further, as they had the highest MMP-2 secretion and invadopodia activity (Figure 2). Econazole nitrate and quinine hydrochloride dihydrate-treated LN229 and MU41 cells showed a decrease in MMP-2 secretion, while flunarizine dihydrochloride led to a reduction of MMP-2 secretion in MU41 cells only (Figure 4A,B). Subsequently, we investigated the ability of these drugs to reduce invadopodia-mediated FITC–gelatin degradation (Figure 4C–F). All three drugs resulted in reduced invadopodia-mediated gelatin-degradation activity in both GBM cells lines. Quinine hydrochloride dihydrate treatment
resulted in the greatest reduction in FITC–gelatin degradation in both cell lines. This is consistent with the reduced level of MMP-2 secretion following quinine hydrochloride dihydrate treatment. Interestingly, the level of MMP-2 secretion in flunarizine dihydrochloride-treated LN229 cells (Figure 4A) did not correspond to the inhibitory effect seen in the invadopodia-mediated FITC–gelatin degradation assay, indicating that this drug may influence other factors regulating invadopodia biogenesis.

Figure 4. Ion channel drugs inhibit MMP-2 secretion and invadopodia activity in GBM cells. Gelatin-based zymogram analysis of (A) LN229 and (B) MU41 GBM cells in serum-free conditioned media treated with 10 µM flunarizine dihydrochloride (FL), econazole nitrate (EN), and quinine hydrochloride dihydrate (Q) for 72 h. Representative of n = 2 experiments. (C) LN229 and (D) MU41 GBM cells were seeded on coverslips coated with a thin film of cross-linked FITC-labeled gelatin following 72-h treatment with 10 µM of FL, EN, and Q. Following a 24-h incubation, cells were fixed and stained with rhodamine phalloidin (red) to probe for actin filaments and DAPI (blue) for nuclear staining. Black areas devoid of FITC-labeled gelatin represent areas of gelatin degradation. Graphical representation of (E) LN229 and (F) MU41 invadopodia mediated FITC–gelatin degradative activity (relative to untreated control). Mean of n = 3 independent experiments, error bars represent SEM, * p < 0.05. Scale bar = 20 µm.

2.5. MMP-2 Secretion and Invadopodia Gelatin Degradation Is Enhanced Following Radiation and Temozolomide Treatment

To investigate the impact of RT and TMZ on invadopodia-mediated invasion, GBM cells were treated with 2 Gy RT and 50 µM TMZ. Zymographic analysis of conditioned GBM cell medium highlighted an increase in pro-MMP-2 secretion in both LN229 and MU41 cell lines, while an increase in active-MMP-2 was seen in the LN229 cell line only (Figure 5C). As MMP-2 secretion increased
following RT/TMZ treatment, we next examined the effect of RT/TMZ treatment on the ability of GBM cells to form functional FITC–gelatin-degrading invadopodia. The GBM cell lines showed an increase in the level of invadopodia-mediated FITC–gelatin degradation post-RT/TMZ treatment (Figure 5A,B). The increase in MMP-2 secretion and invadopodia-mediated FITC–gelatin degradation suggests that cells that survive RT/TMZ treatment may acquire a more pro-invasive phenotype.

![Figure 5](image-url)

**Figure 5.** Radiation/temozolomide (R/T) treatment enhances MMP-2 secretion and invadopodia activity in GBM cells (A) LN229 and MU41 GBM cells were seeded and incubated for 24 h on coverslips coated with a thin film of cross-linked FITC-labeled gelatin 24 h post-treatment with R/T (2 Gy/50 µM). Then, the cells were stained with rhodamine–phalloidin (red) for actin filaments and DAPI for nuclei labelling (blue). FITC–gelatin degradation is evident as black areas devoid of FITC-labeled gelatin. (B) Fold change of FITC–gelatin degradation per GBM cell relative to the corresponding untreated cells for each
cell line. Mean of \( n = 3 \) independent experiments, error bars represent SEM. Scale bar = 20 \( \mu m \), applicable to all images in the panel. (C) LN229 and MU41 GBM cells were treated with R/T (2 Gy/50 \( \mu M \)) for 24 h and incubated in serum-free Optimem before conditioned medium was analyzed via gelatin-based zymography. Representative of \( n = 2 \) independent experiments.

### 2.6. Inhibition of RT/TMZ-Induced Invadopodia Activity

We next examined the ability of the selected candidate drugs to reduce RT/TMZ-induced invadopodia activity in the GBM cells. Here, we demonstrate that treatment with flunarizine dihydrochloride, econazole nitrate, and quinine hydrochloride dihydrate resulted in a significant decrease in RT/TMZ induced invadopodia activity in both the LN229 and MU41 GBM cells (Figure 6). The greatest reduction in invadopodia-mediated FITC–gelatin degradation was noted with quinine hydrochloride dihydrate in the MU41 cell line and flunarizine dihydrochloride in the LN229 cell line.

![Figure 6](image_url)

**Figure 6.** Ion channel-targeting drugs reduce radiation and temozolomide enhanced invadopodia activity. (A) LN229 and (B) MU41 GBM cells were subjected to R/T (2 Gy/50 \( \mu M \)) and 10 \( \mu M \) treatment of flunarizine dihydrochloride (FL), econazole nitrate (EN), or quinine hydrochloride dihydrate (Q) for 72 h prior to being seeded a thin film of cross-linked FITC-labeled gelatin. Cells were stained with rhodamine phalloidin (red) to visualize actin filaments and DAPI (blue) for cell nuclei. FITC–gelatin degradation is evident as black areas devoid of FITC-labeled gelatin. Graphical representation of (C) LN229 and (D) MU41 invadopodia-mediated FITC–gelatin degradative activity per GBM cell (relative to R/T treated groups). Mean of \( n = 3 \) independent experiments, error bars represent SEM, * \( p < 0.05 \). Scale bar = 20 \( \mu m \).
With a focus on identifying drugs with dual “anti-invasive” and “cytotoxic” activity on RT/TMZ-resistant GBM cells, we also examined cell viability with the three candidate drugs in RT/TMZ pre-treated cells. While these drugs led to a reduction in cell viability in most cell lines when compared to the RT/TMZ-only treated, only econazole nitrate in conjunction with RT/TMZ significantly reduced the cell viability of LN229 and U87MG cells when compared to RT/TMZ-only treated cells (Figure 7).

Figure 7. Econazole nitrate can further reduce cell viability following R/T treatment. LN229, U87MG and MU41 GBM cells were treated R/T (2 Gy/50 µM) and 10 µM of each candidate drug: flunarizine dihydrochloride (FL), econazole nitrate (EN), and quinine hydrochloride dihydrate (Q) for 7 days. Subsequently, cell viability was determined using an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell proliferation assay. Cell viability is represented as a percentage relative to the control cells. Mean of n = 3 experiments, error bars represent SEM, * p < 0.05 (relative to R/T).

3. Discussion

Despite a multi-modal treatment approach involving maximal-safe surgical resection, adjuvant radiotherapy, and chemotherapy, GBM remains invariably fatal, which is facilitated by infiltrative growth into the surrounding healthy brain tissue [44]. Tumor cell invasion is a complex process involving cancer cell cytoskeletal changes and remodeling of the ECM mediated by invadopodia [14,45–47]. Ion channels have been shown to facilitate various aspects of cancer progression, including invasion [48]. Koltai [49] has proposed a role for sodium ion channels in protease secretion, while potassium channels can contribute to an invasive phenotype through the altered regulation of intracellular Ca^{2+} levels, leading to cytoskeletal changes [19,49]. Importantly, the relevance of invadopodia and ion channels in GBM can be highlighted by the overexpression of key invadopodia regulators (Table 1) and ion channels in GBM tissue (Table 2) and their impact on glioma patient survival (Figure 1).

The aim of this work was to screen a panel of 20 ion channel-targeting drugs for their ability to select candidate drugs that inhibit GBM cell viability and invadopodia activity. This study identified three drugs that behaved in a “dualistic” manner, reducing both cell viability and invadopodia activity. The shortlisted drugs were flunarizine dihydrochloride (a calcium antagonist approved for use for the prevention of migraines) [50,51], econazole nitrate (an anti-fungal calcium antagonist) [52], and quinine hydrochloride dihydrate (an anti-malarial potassium channel blocker) [53]. A decrease in MMP-2 secretion (Figure 4A,B) was observed with econazole nitrate and quinine hydrochloride dihydrate
in both the LN229 and MU41 GBM cell lines, while flunarizine dihydrochloride resulted in reduced MMP-2 secretion only in the MU41 cell line.

Furthermore, treatment with the three shortlisted ion channel drugs revealed a statistically significant reduction in the level of invadopodia-mediated FITC–gelatin degradation activity in the GBM cell lines (Figure 4C–F), suggesting that all three drugs exhibit an “anti-invadopodia” effect. These findings were consistent with the trend seen in the reduced level of MMP-2 secretion following treatment with econazole nitrate and quinine hydrochloride dihydrate (Figure 4A,B). This was not observed with flunarizine dihydrochloride treatment of the LN229 GBM cell line. Although flunarizine dihydrochloride led to a decrease in invadopodia-mediated FITC–gelatin degradation, the secreted levels of MMP-2 were not significantly altered, indicating that flunarizine dihydrochloride may exert its action on the dynamics of actin cytoskeletal reorganization and subsequent invadopodia formation and not on the secretion of proteases (Figure 4A). Studies have proposed that Ca\(^{2+}\) oscillations are required for the initiation of invadopodia formation [48,54]. Flunarizine dihydrochloride, as a calcium channel antagonist, may reduce Ca\(^{2+}\) oscillations and interfere with the assembly of invadopodia. An impact on the dynamics of invadopodia could lead to a reduction in the number and size of invadopodia (less invadopodia/smaller invadopodia leading to reduced focal FITC–gelatin degradation) [55,56].

Several studies have shown that radiotherapy promotes an invasive and pro-migratory phenotype in GBM [57,58]. Trog et al. [59] showed that RT and TMZ promote the upregulation of pro-invasive proteins such as MMP-2 and MT1-MMP (Membrane type 1-matrix metalloproteinase) in vitro. Consistent with these findings, we demonstrated that clinically relevant doses of RT and TMZ not only led to an increase in the level of MMP-2 secretion but also an increase in invadopodia-mediated FITC–gelatin degradation activity (Figure 5) in GBM cells. Such findings suggest that RT/TMZ treatment promotes an invasive phenotype through invadopodia via the upregulated expression and secretion of MMP-2 in cells that survive treatment [59].

Considering the increase in invasion following RT and TMZ treatment and the “anti-invadopodia” activity of the ion channel drugs, we sought to examine whether treatment with these agents could inhibit treatment-induced enhanced invadopodia activity. While econazole nitrate was the only drug to result in a significant reduction in cell viability following RT/TMZ treatment (Figure 7), all three drugs led to a significant reduction in RT/TMZ-induced invadopodia activity (Figure 6). These results suggest that targeting ion channels can overcome the infiltrative and invasive properties of GBM cells by interfering with invadopodia activity. Flunarizine dihydrochloride and econazole nitrate both block calcium channels and may promote anti-invasive activity. This may occur via the inhibition of the Ca\(^{2+}\) influx required for the activation of other ion channels, such as potassium and chloride channels, which are known to enhance cell migration and invasion [60]. Alternatively, these agents may also act to reduce the invadopodia-mediated focal ECM degradation by blocking the Ca\(^{2+}\) signaling required for the upregulation of proteolytic enzymes such as MMPs and cathepsins [54,60]. As a potassium channel blocker, quinine hydrochloride dihydrate may act by antagonizing potassium channels such as KCa3.1. These channels are involved in mediating cell volume changes required for the reorganization of the actin cytoskeleton and promoting an invasive phenotype in cancer cells [23,24,61].

After identifying drugs that complement the current recommended therapy for GBM patients, one must also consider drug delivery and blood–brain barrier (BBB) penetrance. This is a significant challenge in the use of small molecule compounds in the clinical treatment of GBM where the penetrance of the BBB is limited [62]. Flunarizine dihydrochloride has been shown to have a concentration in the brain that is 10 times higher than in the plasma [50,51,63], whilst quinine has been used for the treatment of malarial-causing parasites in the central nervous system [53,64]. Furthermore, econazole nitrate has also been patented as a neuroprotective agent (US 2010/0298394A1) [52]. This suggests that these drugs can cross the BBB. The predicted BBB penetrance of the candidate ion channel drugs is presented in Table S2. Plasma levels that have been achieved for the candidate agents are listed in Table S3. Therefore, we propose that flunarizine dihydrochloride, econazole nitrate, and quinine hydrochloride dihydrate demonstrate the potential for clinical applicability as an adjuvant treatment.
in combination with the current standard of care for GBM patients. Furthermore, we posit that targeting ion channels to regulate invadopodia activity and inhibit GBM cell invasion is a promising therapeutic avenue that merits further investigation.

4. Materials and Methods

4.1. Ion Channel Drugs

The ion channel drugs used in this study were supplied by Selleckchem, (Selleckchem, Houston, TX, USA) at a concentration of 10 mM in DMSO and were stored at −80 °C until use. The ion channel drugs utilized in this study were included within a larger commercial library supplied by Selleckchem and were screened to provide preliminary data examining their impact on invadopodia activity in GBM cells, as there is evidence that ion channels can regulate tumor cell invasion [19,20].

4.2. Cell Lines and Cell Culture

LN229, U87MG, and MU41 human GBM cell lines were maintained in Dulbecco’s Modified Eagle’s Medium (Life Technologies, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (HyClone, Global Life Sciences Solutions, Parramatta, Australia) and 1% antibiotic-antimycotic (Life Technologies). All cell lines were incubated at 37 °C in a 10% CO2 humidified atmosphere. LN229 and U87MG human GBM cell lines were obtained from the ATCC Biological material repository. The MU41 human GBM cell line was harvested from a GBM patient biopsy sample at the Royal Melbourne Hospital (Melbourne Health Research Ethics Approval Number HREC 2009.116).

4.3. Zymographic Analysis

LN229 and MU41 GBM cells were seeded in 6-well plates and allowed to adhere for 24 h. Cells were washed with sterile phosphate-buffered saline (PBS) before a further 24-h incubation in 2 mL serum-free Optimem® (Thermo Fisher Scientific, Waltham, MA, USA). Then, 200 µL aliquots of the conditioned Optimem® medium were sampled and stored at −80 °C until further use. Optimem® media samples were normalized based on the GBM cell protein concentration using a BCA (bicinchoninic acid) protein assay (Pierce, ThermoFisher Scientific) and by performing densitometry of GAPDH bands in corresponding Western blots. The conditioned medium samples were diluted 1:1 with 2× Novex tris-glycine SDS sample buffer (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) prior to being loaded in 10% gelatin substrate zymogram NuPAGE 10 well pre-cast gels (Novex, Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) and separated at 125 V for 90 min in 1× Novex tris-glycine SDS running buffer. The gels were incubated in 1× Novex zymogram renaturing buffer for 30 min and subsequently incubated in 1× Novex zymogram developing buffer for 30 min. Then, they were incubated overnight at 37 °C with fresh 1× Novex zymogram developing buffer. Following incubation, the gels were washed in distilled water before being stained in SimplyBlue SafeStain (Life Technologies) for 1 h. The gels were washed with distilled water until clear bands (representing gelatinolytic activity) against the undigested blue-stained gel were visible; then, gels were scanned using a flatbed scanner, and image files were used for analysis.

4.4. Invadopodia Degradation Assay

Fluorescein isothiocyanate (FITC)-conjugated gelatin prepared as per previously established protocol [65] was used to coat 25 mm round coverslips. LN229 and MU41 GBM cells were pre-treated with either 2 Gy radiation and 50 µM of temozolomide, or 10 µM of FL, EN, and Q. Following a 72-h incubation, cells were trypsinised and seeded at a density of 1 × 10^5 cells per FITC-conjugated gelatin coverslip and incubated for a further 24 h. The cells were washed with PBS, fixed in 4% paraformaldehyde, and then permeabilized using with 0.2% Triton-X-100. Subsequently, they were stained with rhodamine phalloidin (actin filaments and invadopodia puncta) and DAPI (nuclei), and the coverslips mounted on glass slides with VectaShield (Vector Laboratories, Burlingame, CA, USA)
mounting medium. Images were acquired using a Nikon A1+ confocal microscope system with a Plan Apo VC 60× Oil DIC N2 immersion objective. A total of 10–15 images were acquired for each experimental condition. Image J (Version 1.52e) was used for the analysis of the confocal images. The region and threshold tools were used to define the total area of FITC–gelatin degradation in an image field, while the particle counter macro was used to determine the area of degradation, which was normalized with respect to the number of cells (DAPI-positive nuclei).

4.5. Cell Viability

LN229, U87MG, and MU41 GBM cells were seeded (1 × 10^4 cells/100 µl) in 96-well plates and allowed to adhere for 24 h. Initially, the cells were treated with the 20 ion channel drugs over a concentration range (0.01, 0.1, 1, and 10 µM) (Table 1) for 7 days. Further experiments examining the effect of the shortlisted ion channel agents on cell viability in conjunction with RT and TMZ involved 2 Gy RT and 50 µM of TMZ pre-treatment 4 h prior to the addition of the ion channel drugs (10 µM). A CellTiter 96 Non-Radioactive Cell Proliferation Assay (MTT) (Promega, Alexandria, Australia) was used as per the manufacturer’s instructions to assess cell viability post-treatment.

4.6. Western Blot Analysis

Western blot analysis of GBM cell protein lysates (20 µg) was performed using NuPAGE 4–12% Bis-Tris pre-cast gels (Invitrogen) and transferred onto a 0.45 µm nitrocellulose blotting membrane (GE Healthsciences, Parramatta, Australia). The membrane was blocked in 3% bovine serum albumin in 1% TBST (Tris-buffered saline with Tween) for 1 h prior to overnight incubation with a primary antibody, including GAPDH, NWASP, Nck-1, phospho-cortactin (1:1000, Cell Signalling Technologies, Danvers, MA, USA), MMP-2, c-Src, cortactin, and Tks5 (1:1000, Santa Cruz Biotechnology). The membrane was subsequently incubated with the appropriate secondary antibody and developed using enhanced chemiluminescence reagent (GE Healthcare, Melbourne, Australia) and exposure onto Fujifilm Super RX film.

4.7. Oncomine Data Mining

Differential mRNA and DNA expression levels of invadopodia regulators and ion channels in GBM tissue were retrieved from the Oncomine™ v4.5 (www.oncomine.org Compendia Bioscience™, Ann Arbor, MI, USA, part of Life Technologies) database. Oncomine™ is an online cancer microarray database containing 715 datasets (86,733 samples) compiled from various studies. The threshold for inclusion for data analysis was set to \( p < 0.05 \) for significance and an mRNA expression fold difference of >2. All data are log transformed, and the standard deviation is normalized to one per array studied. A list of all analyzed genes is provided in Table S1. Further details regarding the Oncomine™ analyses are provided in the Supplementary Methods.

4.8. SurvExpress

Glioma patient survival analysis was conducted using gene expression datasets deposited in the SurvExpress (http://bioinformatica.mty.itesm.mx/SurvExpress) database [66]. SurvExpress is an online database for evaluating cancer gene expression data using survival analysis. Data sourced from the SurvExpress platform was used for the survival analysis of invadopodia regulator and ion channel gene co-expression in glioma patients. Further details regarding the SurvExpress analyses are provided in the Supplementary Methods.

4.9. Statistical Analysis

Statistical significance was determined using an unpaired, unequal variance, two-tailed t-test with the use of GraphPad Prism 7 (Prism 7.00 for Windows, GraphPad Software, La Jolla, CA, USA,
Values were considered statistically significant if the $p < 0.05$. In all figures * denotes $p < 0.05$ and error bars represent the standard error of the mean (SEM).

5. Conclusions

During recent years, studies have been investigating the role of invadopodia in mediating cancer invasion. GBM, the most common primary brain tumor, is a highly proliferative and invasive cancer, and the current standard therapy involving surgical resection, radiotherapy, and chemotherapy (temozolomide) is insufficient to eradicate the tumor. Therefore, new therapies are required to not only reduce the number of cells surviving the current therapy but also to reduce the neurologically destructive invasive ability of the GBM cells. Ion channels have emerged as contributors to tumor pathophysiology in the various hallmarks of cancer including cell proliferation, migration, and invasion via their capacity in cell volume regulation. The data from our current study demonstrates that there is potential for repurposing ion channel agents with ion channel targets as novel prospective therapeutic agents to be utilized in targeting the invasive GBM cells that survive the current treatment for GBM patients.

Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/10/2888/s1, Figure S1: Cell viability profile of GBM cells (LN229, U87MG, MU41) following treatment with ion channel drugs, Table S1: Invadopodia regulator genes and ion channel genes utilized in the analyses of online gene expression GBM datasets deposited within the Oncomine® and SurvExpress databases, Figure S2: The uncropped Western Blot figure, Table S2: Candidate drug predicted blood–brain barrier penetrance properties. We examined information on the three candidate drugs, flunarazine dihydrochloride, quinine hydrochloride dihydrate, and econazole nitrate present in the online database, ‘DrugBank’(go.drugbank.com), Table S3: Clinically achievable plasma levels of candidate ion channel drugs.

Author Contributions: Conceptualization, S.S.S.; Methodology, S.S.S.; Formal analysis, M.D.; Investigation, M.D. and N.G.; Data Curation, M.D. and N.G.; writing—original draft preparation, M.D., T.M. and S.S.S.; writing—review and editing, M.D., N.G., A.P.M., A.H.K., J.D., T.M., and S.S.S.; Supervision, S.S.S.; Project administration, S.S.S.; Funding Acquisition, S.S.S., A.H.K. and J.D. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the following funding sources: Perpetual IMPACT Philanthropy Grant IPAP2017/0766 and The Royal Melbourne Hospital Neuroscience Foundation.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ellor, S.V.; Pagano-Young, T.A.; Avgeropoulos, N.G. Glioblastoma: Background, standard treatment paradigms, and supportive care considerations. J. Law Med. Ethic. 2014, 42, 171–182. [CrossRef] [PubMed]
2. Delgado-López, P.D.; Corrales-García, E.M. Survival in glioblastoma: A review on the impact of treatment modalities. Clin. Transl. Oncol. 2016, 18, 1062–1071. [CrossRef] [PubMed]
3. Zygogianni, A.; Protopapa, M.; Kougioumtzopoulou, A.; Simopoulou, F.; Nikoloudi, S.; Kouloulias, V. From imaging to biology of glioblastoma: New clinical oncology perspectives to the problem of local recurrence. Clin. Transl. Oncol. 2018, 20, 989–1003. [CrossRef] [PubMed]
4. Goodenberger, M.L.; Jenkins, R.B. Genetics of adult glioma. Cancer Genet. 2012, 205, 613–621. [CrossRef]
5. Taylor, O.G.; Brzozowski, J.S.; Skelding, K.A. Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets. Front. Oncol. 2019, 9, 1–11. [CrossRef]
6. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N. Engl. J. Med. 2005, 352, 987–996. [CrossRef] [PubMed]
7. Lee, S.Y. Temozolomide resistance in glioblastoma multiforme. Gene Funct. Dis. 2016, 3, 198–210. [CrossRef] [PubMed]
8. Paw, I.; Carpenter, R.C.; Watabe, K.; Debinski, W.; Lo, H.-W. Mechanisms regulating glioma invasion. Cancer Lett. 2015, 362, 1–7. [CrossRef] [PubMed]
9. Nakada, M.; Nakada, S.; DeMuth, T.; Tran, N.L.; Hoelzinger, D.B.; Berens, M.E. Molecular targets of glioma invasion. Cell. Mol. Life Sci. 2007, 64, 458–478. [CrossRef] [PubMed]
10. De Gooijer, M.C.; Navarro, M.G.; Bernardes, R.; Wurdinger, T.; Van Tellingen, O. An Experimenter’s Guide to Glioblastoma Invasion Pathways. *Trends Mol. Med.* 2018, 24, 763–780. [CrossRef]

11. Brown, G.T.; Murray, G.I. Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis. *J. Pathol.* 2015, 237, 273–281. [CrossRef] [PubMed]

12. Artym, V.V.; Zhang, Y.; Seillier-Moiseiwitsch, F.; Yamada, K.M.; Mueller, S.C. Dynamic Interactions of Cortactin and Membrane Type 1 Matrix Metalloproteinase at Invadopodia: Defining the Stages of Invadopodia Formation and Function. *Cancer Res.* 2006, 66, 3034–3043. [CrossRef] [PubMed]

13. Paz, H.; Pathak, N.; Yang, J. Invading one step at a time: The role of invadopodia in tumor metastasis. *Oncogene* 2013, 33, 4193–4202. [CrossRef] [PubMed]

14. Sibony-Benyamini, H.; Gil-Henn, H. Invadopodia: The leading force. *Eur. J. Cell Biol.* 2012, 91, 896–901. [CrossRef] [PubMed]

15. Yamaguchi, H.; Pixley, F.; Condeelis, J. Invadopodia and podosomes in tumor invasion. *Eur. J. Cell Biol.* 2006, 85, 213–218. [CrossRef] [PubMed]

16. Stylii, S.S.; Stacey, T.T.; Kaye, A.H.; Lock, P. Prognostic significance of Tks5 expression in gliomas. *J. Clin. Neurosci.* 2012, 19, 436–442. [CrossRef]

17. Stylii, S.S.; Kaye, A.H.; Lock, P. Invadopodia: At the cutting edge of tumour invasion. *J. Clin. Neurosci.* 2008, 15, 725–737. [CrossRef]

18. Buccione, R.; Caldieri, G.; Ayala, I. Invadopodia: Specialized tumor cell structures for the focal degradation of the extracellular matrix. *Cancer Metastasis Rev.* 2009, 28, 137–149. [CrossRef]

19. Prevarskaya, N.; Skryma, R.; Shuba, Y. Ion channels and the hallmarks of cancer. *Trends Mol. Med.* 2010, 16, 107–121. [CrossRef]

20. Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The Next Generation. *Cell* 2011, 144, 646–674. [CrossRef]

21. Joshi, A.D.; Parsons, D.W.; Velculescu, V.E.; Riggins, G.J. Sodium ion channel mutations in glioblastoma patients correlate with shorter survival. *Mol. Cancer* 2011, 10, 17. [CrossRef] [PubMed]

22. Pollak, J.; Rai, K.G.; Funk, C.C.; Arora, S.; Lee, E.; Zhu, J.; Price, N.D.; Paddison, P.J.; Ramirez, J.-M.; Rostomily, R.C. Ion channel expression patterns in glioblastoma stem cells with functional and therapeutic implications for malignancy. *PLoS ONE* 2012, 7, e31316. [CrossRef] [PubMed]

23. Cuddapah, V.A.; Robel, S.; Watkins, S.; Sontheimer, H. A neurocentric perspective on glioma invasion. *Nat. Rev. Neurosci.* 2014, 15, 455–465. [CrossRef] [PubMed]

24. Cuddapah, V.A.; Turner, K.L.; Seifert, S.; Sontheimer, H. Bradykinin-induced chemotaxis of human gliomas requires the activation of KCa3.1 and ClC-3. *J. Neurosci.* 2013, 33, 1427–1440. [CrossRef] [PubMed]

25. D’Alessandro, G.; Ecatalano, M.; Sciaccaluga, M.; Chece, G.; Cipriani, R.; Rosito, M.; Grimaldi, A.; Lauro, C.; Cantore, G.; Santoro, A.; et al. KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo. *Cell Death Dis.* 2013, 4, e773. [CrossRef]

26. Turner, K.L.; Honasoge, A.; Robert, S.M.; McFerrin, M.M.; Sontheimer, H. A proinvasive role for the Ca(2+) -activated K(+) channel KCa3.1 in malignant glioma. *Glia* 2014, 62, 971–981. [CrossRef]

27. Deliot, N.; Constantin, B. Plasma membrane calcium channels in cancer: Alterations and consequences for cell proliferation and migration. *Biochim. Biophys. Acta. (BBA)-Biomembr.* 2015, 1848, 2512–2522. [CrossRef]

28. Zhang, Y.; Zhang, J.; Jiang, D.; Zhang, N.; Qian, Z.; Liu, C.; Tao, J. Inhibition of T-type Ca2+ channels by endostatin attenuates human glioblastoma cell proliferation and migration. *Br. J. Pharmacol.* 2012, 166, 1247–1260. [CrossRef]

29. Simon, O.J.; Müntefering, T.; Grauer, O.M.; Meuth, S.G. The role of ion channels in malignant brain tumors. *J. Neuro-Oncol.* 2015, 125, 225–235. [CrossRef]

30. Stock, C.; Ludwig, F.T.; Hanley, P.J.; Schwab, A. Roles of Ion Transport in Control of Cell Motility. *Compr. Physiol.* 2013, 3, 59–119. [CrossRef]

31. Molenaar, R.J. Ion Channels in Glioblastoma. *ISRN Neurol.* 2011, 2011, 1–7. [CrossRef] [PubMed]

32. Sela, L.; Ferde, H.E.; Netland, I.A.; Leiss, L.; Skeie, B.S.; Enger, P. Øyvind Drug repurposing in cancer. *Pharmacol. Res.* 2017, 124, 74–91. [CrossRef] [PubMed]

33. Pushpakom, S.; Iorio, F.; Eyers, P.A.; Escott, K.J.; Hopper, S.; Wells, A.; Doig, A.J.; Guilliams, T.; Latimer, J.; McNamee, C.; et al. Drug repurposing: Progress, challenges and recommendations. *Nat. Rev. Drug Discov.* 2018, 17, 41–58. [CrossRef] [PubMed]
34. Bredel, M.; Bredel, C.; Juric, D.; Harsh, G.R.; Vogel, H.; Recht, L.D.; Sikic, B.I. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. *Cancer Res.* **2005**, *65*, 8679–8689. [CrossRef]

35. Liang, Y.; Diehn, M.; Watson, N.P.; Bollen, A.W.; Aldape, K.D.; Nicholas, M.K.; Lamborn, K.R.; Berger, M.S.; Botstein, D.; Brown, P.O.; et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 5814–5819. [CrossRef]

36. Murat, A.; Migliavacca, E.; Gorlia, T.; Lambiv, W.L.; Shay, T.; Hamou, M.-F.; De Tribolet, N.; Regli, L.; Wick, W.; Kouwenhoven, M.C.; et al. Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated with Resistance to Concomitant Chemoradiotherapy in Glioblastoma. *J. Clin. Oncol.* **2008**, *26*, 3015–3024. [CrossRef]

37. Sun, L.; Hui, A.-M.; Su, Q.; Vortmeyer, A.; Kotliarov, Y.; Pastorino, S.; Passaniti, A.; Menon, J.; Walling, J.; Bailey, R.; et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. *Cancer Cell* **2006**, *9*, 287–300. [CrossRef]

38. Yamanaka, R.; Arao, T.; Yajima, N.; Tsuchiya, N.; Homma, J.; Tanaka, R.; Sano, M.; Oide, A.; Sekijima, M.; Nishio, K. Identification of expressed genes characterizing long-term survival in malignant glioma patients. *Oncogene* **2006**, *25*, 5994–6002. [CrossRef]

39. Beroukhim, R.; Getz, G.; Nghiemphu, L.; Barretina, J.; Hsueh, T.; Linhart, D.; Vivanco, I.; Lee, J.C.; Huang, J.H.; Alexander, S.; et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 20007–20012. [CrossRef]

40. Lee, Y.; Scheck, A.C.; Cloughesy, T.; Lai, A.; Dong, J.; Farooqi, H.K.; Liau, L.M.; Horvath, S.; Mischel, P.S.; Nelson, S. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. *BMC Med. Genom.* **2008**, *1*, 52. [CrossRef]

41. Shai, R.; Shi, T.; Kremen, T.J.; Horvath, S.; Liu, L.M.; Cloughesy, T.F.; Mischel, P.S.; Nelson, S.F. Gene expression profiling identifies molecular subtypes of gliomas. *Oncogene* **2003**, *22*, 4918–4923. [CrossRef] [PubMed]

42. Nutt, C.L.; Mani, D.R.; Betensky, R.A.; Tamayo, P.; Cairncross, J.G.; Ladd, C.; Pohl, U.; Hartmann, C.; McLaughlin, M.E.; Batchelor, T.; et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. *Cancer Res.* **2003**, *63*, 1602–1607. [PubMed]

43. Freije, W.A.; Castro-Vargas, F.E.; Fang, Z.; Horvath, S.; Cloughesy, T.; Liu, L.M.; Mischel, P.S.; Nelson, S. Gene Expression Profiling of Gliomas Strongly Predicts Survival. *Cancer Res.* **2004**, *64*, 6503–6510. [CrossRef] [PubMed]

44. Olar, A.; Aldape, K.D. Using the molecular classification of glioblastoma to inform personalized treatment. *J. Pathol.* **2014**, *232*, 165–177. [CrossRef]

45. Saykali, B.A.; El-Sibai, M. Invadopodia, Regulation, and Assembly in Cancer Cell Invasion. *Cell Commun. Adhes.* **2014**, *21*, 207–212. [CrossRef]

46. Mao, L.; Whitehead, C.A.; Paradiso, L.; Kaye, A.H.; Morokoff, A.P.; Luwor, R.B.; Styli, S.S. Enhancement of invadopodia activity in glioma cells by sublethal doses of irradiation and temozolomide. *J. Neurosurg.* **2018**, *129*, 598–610. [CrossRef]

47. Whitehead, C.A.; Nguyen, H.P.; Morokoff, A.P.; Luwor, R.B.; Paradiso, L.; Kaye, A.H.; Mantamadiotis, T.; Styli, S.S. Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved Drugs. *Transl. Oncol.* **2018**, *11*, 1406–1418. [CrossRef]

48. Prevorskaya, N.; Skryma, R.; Shuba, Y. Ion Channels in Cancer: Are Cancer Hallmarks Oncochannelopathies? *Physiol. Rev.* **2018**, *98*, 559–621. [CrossRef]

49. Kolstai, T. Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs. *F1000Research* **2015**, *4*, 297. [CrossRef]

50. Katak, M.; T Mani Senthil Kumar, K.; Rajkumari, A. Neuropsychopharmacological profiling of flunarizine: A calcium channel blocker. *Int. J. Pharmatech Res.* **2010**, *2*, 1703–1713.

51. Fischer, W.; Kittner, H.; Regenthal, R.; De Sarro, G. Anticonvulsant profile of flunarizine and relation to Na(+) channel blocking effects. *Basic Clin. Pharmacol. Toxicol.* **2004**, *94*, 79–88. [CrossRef] [PubMed]

52. Steinert, J.P.; Nath, A.; Haughey, N. Antifungal Agents as Neuroprotectants. US Patent 2010/0298394A1, 25 November 2010.

53. Golden, E.B.; Cho, H.-Y.; Hofman, F.M.; Louie, S.G.; Schönthal, A.H.; Chen, T.C. Quinoline-based antimalarial drugs: A novel class of autophagy inhibitors. *Neurosurg. Focus* **2015**, *38*, E12. [CrossRef] [PubMed]
54. Iamshanova, O.; Pla, A.F.; Prevarskaya, N. Molecular mechanisms of tumour invasion: Regulation by calcium signals. *J. Physiol.* 2017, 595, 3063–3075. [CrossRef] [PubMed]

55. Hoskin, V.; Szeto, A.; Ghaffari, A.; Greer, P.A.; Côté, G.P.; Elliott, B.E. Ezrin regulates focal adhesion and invadopodia dynamics by altering calpain activity to promote breast cancer cell invasion. *Mol. Biol. Cell* 2015, 26, 3463–3479. [CrossRef] [PubMed]

56. Brisson, L.; Alfaroük, K.; Goré, J.; Roger, S. pH regulators in invadosomal functioning: Proton delivery for matrix tasting. *Eur. J. Cell Biol.* 2012, 91, 847–860. [CrossRef] [PubMed]

57. Wild-Bode, C.; Weller, M.; Rims, N.; Dicks, J.; Wic, W. Sublethal irradiation promotes migration and invasiveness of glioma: Implications for radiotherapy of human glioblastoma. *Cancer Res.* 2001, 61, 2744–2750. [PubMed]

58. Wang, S.-C.; Yu, C.-F.; Hong, J.-H.; Tsai, C.-S.; Chi, C.-S. Radiation Therapy-Induced Tumor Invasiveness Is Associated with SDF-1-Regulated Macrophage Mobilization and Vasculogenesis. *PLoS ONE* 2013, 8, e69182. [CrossRef]

59. Trog, D.; Yeghiazaryan, K.; Fountoulakis, M.; Friedlein, A.; Moenkmann, H.; Haertel, N.; Schueller, H.; Breipohl, W.; Schild, H.; et al. Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells. *Eur. J. Pharmacol.* 2006, 542, 8–15. [PubMed]

60. Schwab, A.; Stock, C. Ion channels and transporters in tumour cell migration and invasion. *Philos. Trans. R. Soc. B Biol. Sci.* 2014, 369, 20130102. [CrossRef]

61. Thompson, E.G.; Sontheimer, H. A role for ion channels in perivascular glioma invasion. *Eur. Biophys. J.* 2016, 45, 635–648. [CrossRef]

62. Munson, J.M.; Bonner, M.Y.; Fried, L.; Hofmekler, J.; Arbiser, J.L.; Bellamkonda, R.V. Identifying new small molecule anti-invasive compounds for glioma treatment. *Cell Cycle* 2013, 12, 2200–2209. [CrossRef] [PubMed]

63. Ciancarelli, I.; Tozzi-Ciancarelli, M.G.; Di Massimo, C.; Marini, C.; Carolei, A. Flunarizine Eects on Oxidative Stress in Migraine Patients. *Cephalalgia* 2004, 24, 528–532. [PubMed]

64. Bebin, M.; Bleck, T.P. New Anticonvulsant Drugs. *Drugs* 1994, 48, 153–171. [CrossRef] [PubMed]

65. Stylli, S.S.; Stacey, T.T.I.; Verhagen, A.M.; Xu, S.S.; Pass, L.; Courtneidge, S.A.; Lock, P.; I, S.T.T. Nck adaptor proteins link Tks5 to invadopodia actin regulation and ECM degradation. *J. Cell Sci.* 2009, 122, 2727–2740. [CrossRef]

66. Aguirre-Gamboa, R.; Gomez-Rueda, H.; Martinez-Ledesma, E.; Martinez-Torteya, A.; Chacolla-Huaringa, R.; Rodriguez-Barrientos, A.; Tamez-Peña, J.G.; Trevino, V. SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis. *PLoS ONE* 2013, 8, e74250. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
